Euro-Med Laboratories PhilippinesPHS:EURO +4.81%84 Return-on-Tangible-Equity is 5.66% as of Mar. 2026, which is 9% below its 10-year median of 6.22. GuruFocus rates PHS:EURO with a GF Score™ of 84/100 and a GF Value™ of ₱1.03 (Fairly Valued). The stock has 7 warning signs investors should review. Among 897 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 51.84% on this metric.
The historical rank and industry rank for Euro-Med Laboratories Philippines's Return-on-Tangible-Equity or its related term are showing as below:
PHS:EURO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.2 Med: 6.22 Max: 8.38
Current: 8.38
During the past 13 years, Euro-Med Laboratories Philippines's highest Return-on-Tangible-Equity was 8.38%. The lowest was 3.20%. And the median was 6.22%.
PHS:EURO's Return-on-Tangible-Equity is ranked better than 51.84% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs PHS:EURO: 8.38
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Euro-Med Laboratories Philippines Return-on-Tangible-Equity Related Terms
Euro-Med Laboratories Philippines Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.66% mean?
Euro-Med Laboratories Philippines (PHS:EURO) has a Return-on-Tangible-Equity of 5.66% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Euro-Med Laboratories Philippines and its competitors. This is near median its historical median of 6.22. Over the past decade, Euro-Med Laboratories Philippines' Return-on-Tangible-Equity has ranged from 3.20 to 8.38. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #432 out of 897 companies in the Drug Manufacturers industry, placing it in the top 48.2%.
Is Euro-Med Laboratories Philippines' Return-on-Tangible-Equity too high?
Euro-Med Laboratories Philippines' current Return-on-Tangible-Equity of 5.66% is near median its 10-year median of 6.22. Over the past 10 years, this metric has ranged from a low of 3.20 to a high of 8.38. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Euro-Med Laboratories Philippines' value of 5.66% is 28.4% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #432 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #432 out of 897 companies for Return-on-Tangible-Equity. This puts Euro-Med Laboratories Philippines in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Euro-Med Laboratories Philippines' value of 5.66% is 28.4% below this benchmark. Historically, Euro-Med Laboratories Philippines' own Return-on-Tangible-Equity has ranged from 3.20 to 8.38 over the past decade. While the company's 10-year median is 6.22 vs. the industry median of 7.90, Euro-Med Laboratories Philippines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current Return-on-Tangible-Equity of 5.66% is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current Return-on-Tangible-Equity is 5.66%, which is near median its own 10-year median of 6.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.03, compared to a current price of ₱1.09 — trading 5.8% above its estimated fair value. The current Return-on-Tangible-Equity is 5.66%, which is near median its 10-year median of 6.22 and 28.4% below the Drug Manufacturers industry median of 7.90. Euro-Med Laboratories Philippines' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current Return-on-Tangible-Equity is 5.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.09 is trading 5.8% above its estimated GF Value™ of ₱1.03.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
Return-on-Tangible-Equity: 5.66% (near median its 10-year median of 6.22)
GF Value™: ₱1.03 vs. price of ₱1.09 (5.8% above fair value)
Industry Position: 28.4% below the Drug Manufacturers median (#432 of 897)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
84GF Score
Get the complete analysis for PHS:EURO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
